Handelsbanken Fonder AB cut its position in InMode Ltd. (NASDAQ:INMD - Free Report) by 78.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 27,100 shares of the healthcare company's stock after selling 100,997 shares during the quarter. Handelsbanken Fonder AB's holdings in InMode were worth $453,000 at the end of the most recent quarter.
Several other large investors have also modified their holdings of the company. Atlas Legacy Advisors LLC purchased a new stake in InMode in the 4th quarter valued at approximately $848,000. D.A. Davidson & CO. lifted its position in shares of InMode by 5.7% in the fourth quarter. D.A. Davidson & CO. now owns 43,651 shares of the healthcare company's stock valued at $729,000 after acquiring an additional 2,373 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in InMode by 14.6% in the 4th quarter. Principal Financial Group Inc. now owns 99,562 shares of the healthcare company's stock valued at $1,663,000 after purchasing an additional 12,661 shares in the last quarter. Harvey Capital Management Inc. boosted its position in InMode by 1.4% during the fourth quarter. Harvey Capital Management Inc. now owns 51,490 shares of the healthcare company's stock worth $860,000 after acquiring an additional 700 shares during the last quarter. Finally, Meritage Portfolio Management boosted its holdings in shares of InMode by 12.3% during the fourth quarter. Meritage Portfolio Management now owns 16,575 shares of the healthcare company's stock worth $277,000 after purchasing an additional 1,810 shares during the last quarter. 68.04% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several analysts have recently issued reports on INMD shares. Barclays boosted their price objective on shares of InMode from $26.00 to $29.00 and gave the company an "overweight" rating in a research note on Wednesday, February 5th. Needham & Company LLC restated a "hold" rating on shares of InMode in a research note on Tuesday, February 4th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $22.25.
Read Our Latest Stock Analysis on InMode
InMode Trading Up 0.3 %
NASDAQ:INMD traded up $0.06 during mid-day trading on Thursday, hitting $19.32. The stock had a trading volume of 446,691 shares, compared to its average volume of 916,788. The company has a 50 day simple moving average of $17.67 and a 200-day simple moving average of $17.47. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of 8.21 and a beta of 2.13. InMode Ltd. has a 52 week low of $14.87 and a 52 week high of $23.38.
InMode Profile
(
Free Report)
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Recommended Stories
Before you consider InMode, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InMode wasn't on the list.
While InMode currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
